BLUEHOLE-NEW-CONSUMPTION
29.3.2022 04:15:10 CEST | Business Wire | Press release
China’s leading vaping media, Bluehole New Consumption, today publishes an industry comment on SMOORE‘s establishment of the world’s first E&L testing laboratory in the vaping industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220328005929/en/
Here below is the full article:
SMOORE, a global leader in offering vaping technology solutions, today announced the establishment of the world’s first extractable and leachable (E&L) testing laboratory in the vaping industry.
Built in the last half of 2021, this laboratory conducts qualitative and quantitative analytical testing and health risk assessment of E&L substances of electronic atomization components, including metals, plastics and other polymers.
As China’s first electronic atomization company to develop a PMTA (Premarket Tobacco Product Applications)-compliant assessment system, including physical tests, chemical tests, non-clinical testing and health risk assessment, SMOORE also set up this E&L testing laboratory based on PMTA safety requirements.
Moreover, SMOORE's E&L testing laboratory is in collaboration with SMITHERS, a world-leading provider of testing, consulting, information, and compliance services. For years, the two companies have worked closely on PMTA compliance.
Currently, most companies in the vaping industry rely on third-party laboratories for E&L testing while SMOORE has set up an in-house laboratory with comprehensive and advanced testing equipment. It follows the analytical methodology of the world’s leading E&L testing laboratories for medical devices.
As SMOORE’s flagship atomization tech brand, FEELM is able to make full use of SMOORE’s world-class testing and risk assessment system, including this E&L testing laboratory. Since 2021, FEELM has leveraged the laboratory for the safety assessment of its electronic atomization components, to guarantee the quality and reliability of FEELM's new products.
In October 2021, the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK has planned to integrate medicinally licensed e-cigarettes into the National Health Service (NHS). Other countries, including Australia, have also prescribed adult smokers e-cigarettes to reduce smoking rates. As global regulators started embracing e-cigarettes, they are setting higher safety requirements for e-cigarettes, and SMOORE takes the lead to improve the material reliability of e-cigarettes to medical grade.
E&L analytical testing is widely used in the field of pharmaceutical research and development. The E&L compounds of the packaging materials of pharmaceutical products must be tested before launch, to ensure the product safety compliance.
SMOORE's E&L testing laboratory can provide safety assessment for not only e-cigarettes but also electronic atomization products in other sectors. With one of its R&D focus on the application of atomization technology in healthcare and pharmaceutical fields, SMOORE could leverage this laboratory for the development of healthcare atomization innovations.
"The safety of electronic atomization products primarily depends on the chemical composition of e-liquid and the vapor generated by e-liquid atomization, as well as the E&L substances of other materials in contact with human bodies", said Dr. Long, Director of Analytical Testing and Safety Assessment of SMOORE Fundamental Research Center. "Our E&L testing laboratory specializes in the latter."
According to Dr. Long, SMOORE Fundamental Research Center plans to establish and complete a database of E&L substances in electronic atomization components, and will adopt the principle of Good Laboratory Practice (GLP) to ensure the quality and integrity of test data related to non-clinical safety studies. Meanwhile, SMOORE Fundamental Research Center is also looking for partnership with more Chinese medical device providers on E&L testing.
Since 2020, SMOORE has established its own safety standards, SMOORE 3.0, in accordance with the risk assessment guidance of U.S. EPA (Environmental Protection Agency). Above the safety requirements of the Tobacco Products Directive (TPD) of the EU and AFNOR of France, SMOORE 3.0 covers all of the PMTA tests, including both material safety and vapor safety.
To read the original article, please visit: https://www.bluehole.com.cn/news/detail/49078
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005929/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
